(Date:11/24/2009)...s release is available in German . , Whethe...cards: RFID tags (Radio Frequency Identification) ...ife. They make it possible to label objects or goo...ncy. The appropriate scanner can read and process ...be affixed to goods under production conditions of...
(Date:11/24/2009)..., HOUSTON,Nov.24/PRNewswire-FirstCall/--IES(Nasdaq...mmunicationssystemsandservicesforthecommercial,ind...commercialbusinessgrouphasbeenawardedacontractfrom...heLevel4bio-safetylab(BSL-4)replacementfacilityatt...ases(USAMRIID)atFortDetrickinFrederick,Md. ,, T...
(Date:11/24/2009)... Ambassador to also Visit Detro... 2009 -- , , ,Who: David Appia, French Ambassador ... of the Invest in France Agency, , , , ,What: Amb...iscuss recent pro-business initiatives adopted by ...d academic landscape for innovation and developmen...
(Date:11/24/2009)... The New York investment bank K...X:NEU) has agreed an AU$6.7 mil convertible note p...r. The private placement was arranged by KTA Capit...or. , New York (PRWEB) No...ment bank KTA Capital, LLC ("KTA Capital"...
Breaking Biology Technology:Intelligence inside metal components 2Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2...EGO, June 12 Ardea Biosciences, Inc.,(Nasdaq: RD...son to the,Company,s Board of Directors., "We are...ependent,member of our Board of Directors," said B...t and CEO. "Given his broad financial expertise wi... Audit Committee. We look,forward to his insight a...
...M, Mass., June 12 Repligen Corporation,(Nasdaq: ...er and fiscal,year 2008, ended March 31, 2008. Tot...mpared to total revenue of $14,074,000 for fiscal ...222,000 or 37%. Total revenue for,the year consist...revenue., Operating expenses for fiscal year 2008...
..., ON, June 11 /PRNewswire-FirstCall/ - Helix BioPh...company specializing in the field of,cancer therap...s, quarterly,highlights and financial results for ...008., "During the quarter, we made significant ad... compounds," said John Docherty, President,of Heli...
Other Biology Technology:Craig Johnson Joins Ardea Biosciences' Board of Directors 2Craig Johnson Joins Ardea Biosciences' Board of Directors 3Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 2Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 3Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 4Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 5Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 6Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 7Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 8Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 9Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 10Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 11Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 12Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 13Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 14Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008 15... in-house demand is causing shortages in your labo...tibody. This can cause unwanted distractions, prob...your hard work and endeavour! Bring us your idea a...y. We work under ISO 9001 quality assurance in des...
... in-house demand is causing shortages in your labo...tibody. This can cause unwanted distractions, prob...your hard work and endeavour! Bring us your idea a...y. We work under ISO 9001 quality assurance in des...
Topoisomerase I from Invitrogen
Eco RII (Bst NI) from Roche Applied Science
Biology Products: